given
dramat
impact
pandem
imper
divulg
avail
technolog
potenti
fight
viru
plant
biotechnolog
offer
potenti
solut
pandem
develop
lowcost
vaccin
antibodi
use
therapi
prophylaxi
diagnosi
technolog
produc
plantmad
biopharmaceut
alreadi
establish
two
exampl
therapeut
enzym
enter
market
influenza
vaccin
current
clinic
trial
encourag
result
thu
far
compani
start
develop
antibodi
vaccin
particular
plantmad
antibodi
might
time
produc
approv
human
use
short
term
develop
vaccin
take
longer
time
clinic
evalu
could
conclud
end
nonetheless
candid
obtain
valuabl
tool
futur
outbreak
key
aspect
defin
exploit
technolog
fight
discuss
pandem
caus
viru
dramat
impact
human
lifestyl
econom
social
global
relat
end
march
three
month
emerg
caus
case
death
compar
pandem
mortal
rate
higher
mortal
rate
well
higher
transmiss
spread
countri
territori
area
within
threemonth
period
situat
demand
acceler
race
produc
valid
new
vaccin
antibodi
drug
special
concern
dimens
come
month
impact
pandem
develop
lowincom
countri
context
rapidli
evolv
situat
sever
effort
announc
around
world
involv
pharma
compani
public
institut
acceler
transmiss
blockad
develop
effect
treatment
vaccin
given
urgenc
develop
vaccin
intern
coalit
medicin
regulatori
author
publish
compil
first
global
regulatori
workshop
vaccin
develop
key
point
compris
preclin
data
requir
includ
risk
diseas
enhanc
test
vaccin
latter
aspect
deserv
special
attent
given
preced
candid
vaccin
sar
phenomenon
observ
situat
highlight
need
ration
vaccin
design
avoid
epitop
trigger
undesir
immun
respons
model
develop
evalu
sar
vaccin
candid
valuabl
start
point
perform
preclin
evalu
compris
model
base
mice
ferret
monkey
case
antibodymedi
therapi
passiv
immun
interest
fact
crossreact
viru
viru
suggest
alreadi
develop
biolog
could
enter
arena
fight
therefor
avail
monoclon
antibodi
viru
valuabl
arsen
studi
potenti
treatment
molecular
farm
biotechnolog
applic
involv
use
plant
speci
host
product
highli
valuabl
recombin
protein
includ
antibodi
vaccin
hormon
enzym
initi
effort
plantbas
manufactur
arena
report
three
decad
ago
suffer
low
protein
yield
precari
process
plant
genet
engin
approach
refin
sophist
express
platform
current
avail
allow
obtain
protein
yield
g
protein
per
kg
plant
leav
instanc
cgmp
process
n
benthamiana
plant
grown
subject
transient
transform
trigger
effici
express
target
protein
within
day
plant
leaf
biomass
harvest
process
purifi
target
biopharmaceut
inject
formul
obtain
type
platform
easili
scale
platform
base
plant
biomass
propag
use
bioreactor
suspens
cell
cultur
eg
carrot
rice
cell
moreov
refin
product
process
posit
impact
qualiti
fulfil
requir
regulatori
agenc
eg
complianc
ich
guidelin
sens
work
done
research
achiev
implement
process
prone
scaleup
accord
principl
current
good
manufactur
practic
cgmp
pharmaceut
indic
us
fda
today
plantmad
biopharmaceut
becom
realiti
least
one
product
enter
market
name
taligluceras
alfa
carrotmad
enzym
obtain
bioreactor
prescrib
replac
therapi
diseas
product
close
approv
instanc
clinic
trial
ongo
evalu
influenza
vaccin
produc
medicago
inc
moreov
zmapp
plantmad
monoclon
antibodi
cocktail
place
spotlight
ebola
outbreak
sinc
administ
two
patient
compassion
basi
treat
patient
although
antibodi
shown
better
perform
plantmad
antibodi
cocktail
reveal
potenti
technolog
fight
emerg
diseas
today
glycoengin
approach
avail
yield
specif
antibodi
glycoform
allow
optim
function
activ
safeti
target
antibodi
moreov
function
singl
chain
antibodi
also
produc
plant
system
provid
simpler
molecul
viral
neutral
plantmad
antigen
antibodi
also
conveni
tool
diagnosi
provid
lowcost
protein
preserv
antigen
determin
specif
upon
extraordinari
unpreced
public
health
crisi
caus
solid
involv
collabor
across
govern
societi
busi
urgent
requir
context
especi
consid
pandem
initi
stage
develop
lowincom
countri
govern
academ
institut
turn
attent
lowcost
technolog
product
biopharmaceut
given
process
product
plantmad
vaccin
therapeut
enzym
antibodi
alreadi
establish
rapid
progress
gener
candid
anticip
might
compris
immedi
preexist
viru
antibodi
could
crossreact
viru
vaccin
base
vlp
assembl
protein
current
consid
primari
target
viru
neutral
figur
least
two
compani
announc
begin
race
develop
plantmad
vaccin
antibodi
viru
day
access
viru
protein
sequenc
product
vlp
transient
express
system
announc
compani
medicago
inc
wwwmedicagocomenpipelin
therefor
rapid
progress
expect
develop
compani
estim
hold
product
capac
million
dose
month
vlpsbase
vaccin
attract
product
capac
number
dose
could
allow
instanc
immun
million
us
adult
sever
risk
critic
ill
death
infect
viru
addit
develop
epitopebas
vaccin
advis
diminish
possibl
diseas
enhanc
ibio
inc
also
vlp
vaccin
pipelin
wwwibioinccom
pipelin
compani
potenti
enter
race
includ
nomad
wwwnomadbiosciencecom
ventria
ventria
com
greenov
biopharmaceut
wwwgreenov
com
protalix
wwprotalixcom
kentucki
bioprocess
wwwkentuckybioprocessingcom
academ
institut
doubt
key
role
field
fact
infecti
diseas
research
centr
laval
univers
joint
effort
medicago
develop
therapeut
antibodi
sever
univers
institut
sever
countri
includ
us
germani
uk
south
africa
south
corea
mexico
thailand
work
molecular
farm
field
invest
effort
topic
establish
partnership
institut
special
infecti
diseas
lead
synergi
develop
transgen
plant
stabli
transform
take
long
time
month
therefor
approach
unpract
respond
pandem
nonetheless
transient
transform
approach
offer
rapid
method
express
within
week
effici
express
target
antigen
antibodi
render
inject
formul
despit
expert
opinion
develop
stabli
transform
plant
speci
especi
yield
edibl
biomass
still
necessari
gener
model
oral
vaccin
could
find
nich
postpandem
stage
highli
probabl
viru
becom
season
pathogen
gener
need
constant
immun
program
therefor
alreadi
develop
oral
vaccin
product
platform
use
cope
situat
given
approach
practic
perform
larg
vaccin
campaign
low
cost
easytoimpl
logist
moreov
could
also
use
boost
agent
might
complement
parenter
prime
perform
pure
antigen
scheme
optim
immun
profil
term
protect
system
compart
mucos
compart
could
induc
fact
mucos
immun
consid
superior
potenti
protect
mucos
compart
induct
secretori
iga
respons
could
neutral
viru
sadli
project
impact
pandem
develop
countri
devast
initi
scenario
therefor
urgent
implement
lowcost
product
platform
biolog
fight
scenario
sourc
lowcost
biolog
govern
current
compani
work
molecular
farm
field
eg
medicago
ibio
form
allianc
benefit
unprotect
popul
regard
plantbas
manufactur
contempl
one
altern
although
straightforward
approach
produc
viru
biopharmaceut
reli
convent
platform
ie
cho
cell
yeast
plantmad
biopharmaceut
incorpor
fight
viru
occur
time
develop
accomplish
stretch
cooper
compani
govern
agenc
public
institut
case
vaccin
development
pipelin
necessarili
requir
extens
safeti
efficaci
evalu
take
least
year
accord
estim
medicago
inc
wwwmedicagocomenpipelin
howev
experi
gain
evalu
critic
fight
becom
season
pathogen
case
emerg
new
coronaviru
strain
fact
fda
establish
advanc
technolog
team
stimul
discuss
divulg
feedback
among
fda
staff
prospect
innovatorsdevelop
advanc
manufactur
technolog
action
hope
get
expedit
process
approv
biopharmaceut
produc
innov
platform
especi
emerg
pathogen
sinc
plantmad
biopharmaceut
adopt
systemat
around
world
thu
far
regulatori
agenc
must
increas
knowledg
technolog
adapt
requir
approv
plantmad
vaccin
perhap
achiev
case
regulatori
agenc
display
flexibl
valid
approv
viru
plantmad
biopharmaceut
eg
adaptingsimplifi
regulatori
requir
specif
technolog
regulatori
agenc
acceler
evalu
process
plantmad
biopharmaceut
viru
exist
clinic
trial
plantmad
vaccin
influenza
encourag
find
enzym
alreadi
approv
make
approv
pathway
smoother
develop
lowincom
countri
ultim
benefit
plantbas
technolog
fight
come
month
critic
answer
key
question
main
featur
plantbas
platform
includ
low
cost
scalabl
safeti
divulg
promot
adopt
govern
associ
spinoff
compani
privat
small
compani
seek
crystal
product
benefit
global
health
especi
develop
lowincom
countri
limit
resourc
cope
pandem
paper
fund
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
includ
employ
consult
honoraria
stock
ownership
option
expert
testimoni
grant
patent
receiv
pend
royalti
peer
review
manuscript
relev
financi
relationship
otherwis
disclos
